vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v20i5.2321vsp-2750Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEОсобенности ведения пациентов с псориазом в детском возрасте в период пандемии COVID-19Management of Children with Psoriasis During the COVID-19 Pandemichttps://orcid.org/0000-0003-2252-8570МурашкинН. Н.MurashkinNikolay N.

Мурашкин Николай Николаевич - доктор медицинских наук, заведующий отделением дерматологии с группой лазерной хирургии НМИЦ здоровья детей; доктор медицинских наук, профессор кафедры дерматовенерологии и косметологии ЦГМА; профессор кафедры педиатрии и детской ревматологии Первого МГМУ им. И.М. Сеченова.119991, Москва, Ломоносовский пр-т, д. 2, стр. 1.Тел.: +7 (499) 134-08-89

Moscow.

m_nn2001@mail.ruhttps://orcid.org/0000-0002-6034-8231МатерикинА. И.MaterikinAlexander I.

Москва.

Moscow.

https://orcid.org/0000-0002-8232-8936АмбарчянЭ. Т.AmbarchianEduard T.

Москва.

Moscow.

https://orcid.org/0000-0002-4107-4642ЕпишевР. В.EpishevRoman V.

Москва.

Moscow.

https://orcid.org/0000-0002-0858-8780ОпрятинЛ. А.OpryatinLeonid A.

Москва.

Moscow.

https://orcid.org/0000-0002-0081-0981ИвановР. А.IvanovRoman A.

Москва.

Moscow.

Национальный медицинский исследовательский центр здоровья детей; Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет); Центральная государственная медицинская академияРоссияNational Medical Research Center of Children's Health; Sechenov First Moscow State Medical University (Sechenov University); Central State Medical AcademyRussian FederationНациональный медицинский исследовательский центр здоровья детейРоссияNational Medical Research Center of Children's HealthRussian FederationНИИ педиатрии и охраны здоровья детей ЦКБ РАНРоссияResearch Institute of Pediatrics and Children's Health in “Central Clinical Hospital of the Russian Academy of Sciences”Russian Federation202106112021205441445Copyright © Мурашкин Н.Н., Материкин А.И., Амбарчян Э.Т., Епишев Р.В., Опрятин Л.А., Иванов Р.А., 20212021Мурашкин Н.Н., Материкин А.И., Амбарчян Э.Т., Епишев Р.В., Опрятин Л.А., Иванов Р.А.Murashkin N.N., Materikin A.I., Ambarchian E.T., Epishev R.V., Opryatin L.A., Ivanov R.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/2750

Распространением новой коронавирусной инфекции (COVID-19) продиктовано особое внимание специалистов к пациентам с хроническими заболеваниями, в т.ч. хроническими дерматозами. Высокий риск развития осложнений COVID-19 у больных с псориазом обусловлен особенностями патогенеза заболевания, в частности высокой активностью провоспалительных цитокинов, и применяемыми иммуносупрессивными методами терапии. Псориаз поражает до 1% детей в странах Европы, при этом от 10 до 20% из них переносят болезнь в среднетяжелой или тяжелой форме. Этим детям может потребоваться иммуносупрессивное лечение, в т.ч. генно-инженерная биологическая терапия. О состоянии взрослых и детей, больных псориазом, в период пандемии COVID-19 опубликовано ограниченное количество данных.

The spread of new coronavirus infection (COVID-19) changes specialists' approaches to patients with chronic diseases, including those with chronic dermatoses. The high risk of COVID-19 complications in patients with psoriasis is connected to the features of disease pathogenesis (such as high activity of proinflammatory cytokines) and used immunosuppressive therapy. Psoriasis affects up to 1% of children in Europe, while 10-20% of them have moderate or severe form of disease. These children may require immunosuppressive treatment, including genetically engineered biological therapy. There is only limited data on adults and children with psoriasis during the COVID-19 pandemic.

детипсориазCOVID-19этанерцептchildrenpsoriasisCOVID-19etanerceptСтатья подготовлена при поддержке компании Pfizer.The article has been funded by Pfizer.ReferencesMunster VJ, Koopmans M, van Doremalen N. A novel coronavirus emerging in China — Key questions for impact assessment. N Engl J Med. 2020;382(8):692-694. doi: 10.1056/NEJMp2000929Munster VJ, Koopmans M, van Doremalen N. A novel coronavirus emerging in China — Key questions for impact assessment. N Engl J Med. 2020;382(8):692-694. doi: 10.1056/NEJMp2000929Стопкоронавирус.рф. Доступно по: https://xn--80aesfpebagmfblc0a.xn--p1ai/information. Ссылка активна на 26.10.2021.Stopkoronavirus. rf. (In Russ). Доступно по: https://xn--80aesfpebagmfblc0a.xn--p1ai/information. Ссылка активна на 26.10.2021.World Health Organization. Protect yourself and others from the spread COVID-19. 2020. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public. Accessed on October 26, 2021.World Health Organization. Protect yourself and others from the spread COVID-19. 2020. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public. Accessed on October 26, 2021.Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3Gisondi P, Facheris P, Dapavo P. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol. 2020;183(2):373-374. doi: 10.1111/bjd.19158Gisondi P, Facheris P, Dapavo P. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol. 2020;183(2):373-374. doi: 10.1111/bjd.19158Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385. doi: 10.1038/jid.2012.339Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385. doi: 10.1038/jid.2012.339Menter A, Cordoro KM, Davis DMR. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161-201. doi: 10.1016/j.jaad.2019.08.049Menter A, Cordoro KM, Davis DMR. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161-201. doi: 10.1016/j.jaad.2019.08.049Mahil SK, Dand N, Mason KJ et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2020;147(1):60-71. doi: 10.1016/j.jaci.2020.10.007Mahil SK, Dand N, Mason KJ et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2020;147(1):60-71. doi: 10.1016/j.jaci.2020.10.007Bardazzi F, Loi C, Sacchelli L, Di Altobrando A. Biologic therapy for psoriasis during the covid-19 outbreak is not a choice. J Dermatolog Treat. 2020;31(4):320-321. doi: 10.1080/09546634.2020.1749545Bardazzi F, Loi C, Sacchelli L, Di Altobrando A. Biologic therapy for psoriasis during the covid-19 outbreak is not a choice. J Dermatolog Treat. 2020;31(4):320-321. doi: 10.1080/09546634.2020.1749545Gisondi P, Facheris P, Dapavo P, et al. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the northern Italy experience. Br J Dermatol. 2020;183(2):373-374. doi: 10.1111/bjd.19158Gisondi P, Facheris P, Dapavo P, et al. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the northern Italy experience. Br J Dermatol. 2020;183(2):373-374. doi: 10.1111/bjd.19158Carugno A, Gambini DM, Raponi F, et al. COVID-19 and biologics for psoriasis: a high-epidemic area experience-Bergamo, Lombardy, Italy. J Am Acad Dermatol. 2020;83(1):292-294. doi: 10.1016/j.jaad.2020.04.165Carugno A, Gambini DM, Raponi F, et al. COVID-19 and biologics for psoriasis: a high-epidemic area experience-Bergamo, Lombardy, Italy. J Am Acad Dermatol. 2020;83(1):292-294. doi: 10.1016/j.jaad.2020.04.165Megna M, Ruggiero A, Marasca C, Fabbrocini G. Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatolog Treat. 2020;31(4):328-329. doi: 10.1080/09546634.2020.1757605Megna M, Ruggiero A, Marasca C, Fabbrocini G. Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatolog Treat. 2020;31(4):328-329. doi: 10.1080/09546634.2020.1757605Ebrahimi A, Sayad B, Rahimi Z. COVID-19 and psoriasis: biologic treatment and challenges. J Dermatolog Treat. 2020;1-5. doi: 10.1080/09546634.2020.1789051Ebrahimi A, Sayad B, Rahimi Z. COVID-19 and psoriasis: biologic treatment and challenges. J Dermatolog Treat. 2020;1-5. doi: 10.1080/09546634.2020.1789051Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration. Dermatol Ther. 2020;33(5):e13475. doi: 10.1111/dth.13475Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration. Dermatol Ther. 2020;33(5):e13475. doi: 10.1111/dth.13475Polat AK, Topal IO, Karadag AS, et al. The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul. Dermatol Ther. 2021;34(1):e14691. doi: 10.1111/dth.14691Polat AK, Topal IO, Karadag AS, et al. The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul. Dermatol Ther. 2021;34(1):e14691. doi: 10.1111/dth.14691COVID-19 Situation report, Turkey. 2020. Available online: https://covid19.saglik.gov.tr/Eklenti/37743/0/covid-19-situation-report-v4pdf.pdf. Accessed on October 27, 2021.COVID-19 Situation report, Turkey. 2020. Available online: https://covid19.saglik.gov.tr/Eklenti/37743/0/covid-19-situation-report-v4pdf.pdf. Accessed on October 27, 2021.Beytout Q, Pepiot J, Maruani A, et al. Impact of the COVID-19 pandemic on children with psoriasis. Ann Dermatol Venereol. 2021;148(2):106-111. doi: 10.1016/j.annder.2021.01.005Beytout Q, Pepiot J, Maruani A, et al. Impact of the COVID-19 pandemic on children with psoriasis. Ann Dermatol Venereol. 2021;148(2):106-111. doi: 10.1016/j.annder.2021.01.005Ciuca I.M. COVID-19 in children: an ample review. Risk Manag Healthc Policy. 2020;13:661-669. doi: 10.2147/RMHP.S257180Ciuca I.M. COVID-19 in children: an ample review. Risk Manag Healthc Policy. 2020;13:661-669. doi: 10.2147/RMHP.S257180PsoProtect. Summary data from PsoProtect's first 200 cases. Available online: https://psoprotect.org/current-data. Accessed on October 27, 2021.PsoProtect. Summary data from PsoProtect's first 200 cases. Available online: https://psoprotect.org/current-data. Accessed on October 27, 2021.Mahe E, Maccari F, Ruer-Mulard M, et al. Psoriasis de l'enfant vu en milieu liberal: les aspects cliniques et epidemiologiques different des donnees habituellement publiees. Ann Dermatol Venereol. 2019;146:354-362. doi: 10.1016/j.annder.2019.01.024Mahe E, Maccari F, Ruer-Mulard M, et al. Psoriasis de l'enfant vu en milieu liberal: les aspects cliniques et epidemiologiques different des donnees habituellement publiees. Ann Dermatol Venereol. 2019;146:354-362. doi: 10.1016/j.annder.2019.01.024Skayem C, Cassius C, Ben Kahla M, et al. Teledermatology for COVID-19 cutaneous lesions: substitute or supplement? J Eur Acad Dermatol Venereol. 2020;34(10):e532-e533. doi: 10.1111/jdv.16630Skayem C, Cassius C, Ben Kahla M, et al. Teledermatology for COVID-19 cutaneous lesions: substitute or supplement? J Eur Acad Dermatol Venereol. 2020;34(10):e532-e533. doi: 10.1111/jdv.16630Onsun N, Gunej B, Yabaci A. Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center. Dermatol Ther. 2021;34(1):e14623. doi: 10.1111/dth.14623Onsun N, Gunej B, Yabaci A. Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center. Dermatol Ther. 2021;34(1):e14623. doi: 10.1111/dth.14623Haberman R, Axelrad J, Chen A, Castillo R, et al. Covid-19 in immune-mediated inflammatory diseases-case series from New York. N Engl J Med. 2020;383(1):85-88. doi: 10.1056/NEJMc2009567Haberman R, Axelrad J, Chen A, Castillo R, et al. Covid-19 in immune-mediated inflammatory diseases-case series from New York. N Engl J Med. 2020;383(1):85-88. doi: 10.1056/NEJMc2009567Conti A, Lasagni C, Bigi L, Pellacani G. Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs. J Eur Acad Dermatol Venereol. 2020;34(8):e360-e361. doi: 10.1111/jdv.16587Conti A, Lasagni C, Bigi L, Pellacani G. Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs. J Eur Acad Dermatol Venereol. 2020;34(8):e360-e361. doi: 10.1111/jdv.16587Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and metaanalysis. Expert Opin Drug Saf. 2016;15(sup1):11-34. doi: 10.1080/14740338.2016.1240783Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and metaanalysis. Expert Opin Drug Saf. 2016;15(sup1):11-34. doi: 10.1080/14740338.2016.1240783Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395(10234):1407-1409. doi: 10.1016/S0140-6736(20)30858-8Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395(10234):1407-1409. doi: 10.1016/S0140-6736(20)30858-8Del Valle DM, Kim-Schulze S, Huang H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9Del Valle DM, Kim-Schulze S, Huang H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9Lee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci Immunol. 2020;5(49):eabd1554. doi: 10.1126/sciimmunol.abd1554Lee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci Immunol. 2020;5(49):eabd1554. doi: 10.1126/sciimmunol.abd1554Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999;163(3):1521-1528.Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999;163(3):1521-1528.Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36(12):1681-1690. doi: 10.1002/art.1780361206Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36(12):1681-1690. doi: 10.1002/art.1780361206Ingegnoli F, Fantini F, Favalli E, et al. Inflammatory and pro-thrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factor-alpha blockade. J Autoimmun. 2008;31(2):175-179. doi: 10.1016/j.jaut.2008.07.002Ingegnoli F, Fantini F, Favalli E, et al. Inflammatory and pro-thrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factor-alpha blockade. J Autoimmun. 2008;31(2):175-179. doi: 10.1016/j.jaut.2008.07.002Antunes Brito C, Paiva JG, Pimentel FP, et al. COVID-19 in patients with rheumatological diseases treated with anti-TNF. Ann Rheum Dis. 2021;80(5):e62. doi: 10.1136/annrheumdis-2020-218171Antunes Brito C, Paiva JG, Pimentel FP, et al. COVID-19 in patients with rheumatological diseases treated with anti-TNF. Ann Rheum Dis. 2021;80(5):e62. doi: 10.1136/annrheumdis-2020-218171Yousaf A, Gayam S, Feldman S, et al. Clinical outcomes of CoVid-19 in patients taking tumor necrosis factor inhibitors and/ or methotrexate: a multi-center research network study. J Am Acad Dermatol. 2020;84(1):70-75. doi: 10.1016/j.jaad.2020.09.009Yousaf A, Gayam S, Feldman S, et al. Clinical outcomes of CoVid-19 in patients taking tumor necrosis factor inhibitors and/ or methotrexate: a multi-center research network study. J Am Acad Dermatol. 2020;84(1):70-75. doi: 10.1016/j.jaad.2020.09.009

The authors declare that there are no conflicts of interest present.